About Fluoresentric
Fluoresentric is a Healthcare company based in Park City (United States) founded in 2003. Point-of-care instruments and assays for nucleic acid amplification are developed. Fluoresentric has raised $124.2 thousand across 4 funding rounds. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is Fluoresentric, Inc. Its competitors include Inflammatix, Visby Medical and GenMark Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Fluoresentric was founded in 2003 and is based in Park City, United States. Instruments and assays for point-of-care nucleic acid amplification are developed by the company within the biotechnology sector. Proprietary XCR technology is utilized to reduce PCR amplification times from 30-60 minutes to 5 minutes. Assays are designed for detection of various human, veterinary, and other pathogens.
- Headquarters Park City, United States
- SectorsHealthcare
- Website fluoresentric.com
- Social LinkedIn X
- Legal Name Fluoresentric, Inc.
- Total Equity Funding$124.2K (USD)
in 4 rounds
Funding Insights of Fluoresentric
Fluoresentric has successfully raised a total of $124.2K across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $124,200
- Total Rounds 4
- First Round $24,000
(Mar 2010)
All 4 funding rounds of Fluoresentric with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2015 | Series B | – | – | – | |
| Jun 2014 | $500,000 | Debt – Conventional | – | – | – |
| Aug 2011 | $100,200 | Seed | – | – | – |
| Mar 2010 | $24,000 | Seed | – | – | – |
Timeline of Fluoresentric
3 dated milestones of Fluoresentric across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Fluoresentric is founded.
- Funding First funding round of $24K.
- Funding Latest funding round, Series B,.
Competitors of Fluoresentric
Fluoresentric has 3 listed competitors in our database, 3 of them funded. They include Inflammatix, Visby Medical and GenMark Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. |
Detailed competitors of Fluoresentric
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fluoresentric
Websites that share an audience with Fluoresentric (fluoresentric.com).
Websites whose visitors overlap most with Fluoresentric. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biotechniques.com | biotechniques.com | 100% | #652,069 | – | |
| primerdesign.co.uk | 87% | 3.5K | #5,807,275 | View details | |
tib-molbiol.com | tib-molbiol.com | 87% | – | ||
pcr-encyclopedia.com | pcr-encyclopedia.com | 87% | – | ||
realtimeprimers.org | realtimeprimers.org | 87% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Fluoresentric
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Fluoresentric (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Fluoresentric
Fluoresentric was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Fluoresentric is headquartered in Park City, United States. It is registered at Park City, Utah, United States.
Fluoresentric is a funded company, having raised a total of $124.2K across 4 funding rounds to date. The company's 1st funding round was a Seed of $24K, raised on Mar 2010.
Fluoresentric was founded in 2003 and is based in Park City, United States. Instruments and assays for point-of-care nucleic acid amplification are developed by the company within the biotechnology sector. Proprietary XCR technology is utilized to reduce PCR amplification times from 30-60 minutes to 5 minutes. Assays are designed for detection of various human, veterinary, and other pathogens.
Fluoresentric's top competitors include Visby Medical, Inflammatix and GenMark Diagnostics.
Fluoresentric operates through Fluoresentric, Inc..